Regeneron Pharmaceuticals (NASDAQ: REGN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Regeneron Pharmaceuticals Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Regeneron Pharmaceuticals Company Info
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
News & Analysis
Even in choppy markets, there are smart investments you can make.
Regeneron released positive phase 3 trial results for its therapy Dupixent.
These exchange-traded funds track companies in this biotech space.
These CRISPR stocks could be big winners for patient investors.
Regeneron and Sarepta Therapeutics have been on fire so far this year.
The two companies have seen similar share growth over the past year.
Here are the five best biotech ETFs to invest in right now.
Upcoming binary events could push these stocks to new all-time highs.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 04/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Podcast Episodes
Regeneron Pharmaceuticals stock got a shot in the arm after it announced a possible drug candidate for coronavirus.
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
Positive trial data unveiled at the American Society of Hematology conference makes these top stocks to watch in 2019.
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.
Earnings Transcripts
REGN earnings call for the period ending September 30, 2021.
REGN earnings call for the period ending June 30, 2021.
REGN earnings call for the period ending March 31, 2021.
REGN earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.